Compare USNA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | OMER |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 1.2B |
| IPO Year | 1996 | 2008 |
| Metric | USNA | OMER |
|---|---|---|
| Price | $13.36 | $17.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 174.6K | ★ 1.0M |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $1,060,902,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.96 | $73.59 |
| P/E Ratio | ★ N/A | $23.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.53 | $6.70 |
| 52 Week High | $23.59 | $21.24 |
| Indicator | USNA | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 48.07 |
| Support Level | $12.63 | $16.33 |
| Resistance Level | $15.49 | $19.68 |
| Average True Range (ATR) | 0.68 | 0.95 |
| MACD | -0.14 | 0.04 |
| Stochastic Oscillator | 28.12 | 42.53 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.